Kamada and Chiesi Farmaceutici S.p.A. Mutually Agree to Terminate European Distribution Agreement for Inhaled Alpha-1 Antitrypsin Therapy for Treatment of Alpha-1 Antitrypsin Deficiency

Press Release / Nov. 22, 2017

Kamada announced that the Company and Chiesi Farmaceutici S.p.A., a fully integrated European Pharmaceutical company focused on respiratory disease and special care products, have mutually agreed to terminate the parties’ European distribution agreement related to Kamada’s inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).

Kamada Announces New Supply Agreement with International Organization for KamRAB for Post-Exposure Prophylaxis Against Rabies Infection

Press Release / Nov. 21, 2017

Kamada announced today that it has signed a supply agreement with an undisclosed international organization for KamRAB [rabies immune globulin (Human)].  

Amended Notice of 2017 Annual General Meeting of Shareholders

Press Release / Nov. 10, 2017

On October 26, 2017, Kamada Ltd. announced the 2017 Annual General Meeting of shareholders of the Company to be held on November 30, 2017.


Kamada to Announce Third Quarter 2017 Financial Results and Host Conference Call on November 13

Press Release / Nov. 8, 2017

Kamada announced today that it will release financial results for the third quarter ended September 30, 2017, prior to the open of the U.S. financial markets on Monday, November 13.

Kamada Announces Top-line Results of Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients

Press Release / Nov. 1, 2017

Efficacy trend was demonstrated in the pre-determined subgroup of patients between the ages of 12 to 18, treated with the higher dose of 120mg/kg. The positive trend was observed in this age group for all three key efficacy measures of Type-1 Diabetes.

out of 5 items.